PHARMACOTHERAPEUTICS FOR ADVANCED M M
Pharmacotherapeutics
PRACTICE NURSEforPRESCRIBERS,
Advanced Practice Nurse
M 5TH
M
M
Prescribers,
EDITION
M 5t W M M
M
M
M
M
M
h
OO edition
ROBINSON TESTBANK
Woo Robinson
M
Test Bank M M
M
M M
PharmacotherapeuticsMforMAdvancedMPracticeMNurseMPrescribers,M5thMeditionMWooMRobinsonMTestMBank
ChapterM1.MTheMRoleMofMtheMNurseMPractitionerMasMPrescrib
erMMultipleMChoice
IdentifyMtheMchoiceMthatMbestMcompletesMtheMstatementMorManswersMtheMquestion.
M 1.MNurseMpractitionerMprescriptiveMauthorityMisMregulatedM by:
1. TheMNationalMCouncilMofMStateMBoardsMofMNursing
2. TheMU.S.MDrugMEnforcementMAdministration
3. TheMStateMBoardMofMNursingMforMeachMstate
4. TheMStateMBoardMofMPharmacy
M 2.MTheMbenefitsMtoMtheMpatientMofMhavingManMAdvancedMPracticeMRegisteredMNurseM(APRN)Mpresc
riberMinclude:
1. NursesMknowMmoreMaboutMPharmacologyMthanMotherMprescribersMbecauseMtheyMtak
eMitMbothMinMtheirMbasicMnursingMprogramMandMinMtheirMAPRNMprogram.
2. NursesMcareMforMtheMpatientMfromMaMholisticMapproachMandMincludeMtheMpatien
tMinMdecisionMmakingMregardingMtheirMcare.
3. APRNsMareMlessMlikelyMtoMprescribeMnarcoticsMandMotherMcontrolledMsubstances.
4. APRNsMareMableMtoMprescribeMindependentlyMinMallMstates,MwhereasMaMphysicia
n’sMassistantMneedsMtoMhaveMaMphysicianMsupervisingMtheirMpractice.
M 3.MClinicalMjudgmentMinMprescribingM includes:
1. FactoringMinMtheMcostMtoMtheMpatientMofMtheMmedicationMprescribed
2. AlwaysMprescribingMtheMnewestMmedicationMavailableMforMtheMdiseaseMprocess
3. HandingMoutMdrugMsamplesMtoMpoorMpatients
4. PrescribingMallMgenericMmedicationsMtoMcutMcosts
M 4.MCriteriaMforMchoosingManMeffectiveMdrugMforMaMdisorderM include:
1. AskingMtheMpatientMwhatMdrugMtheyMthinkMwouldMworkMbestMforMthem
2. ConsultingMnationallyMrecognizedMguidelinesMforMdiseaseMmanagement
3. PrescribingMmedicationsMthatMareMavailableMasMsamplesMbeforeMwritingMaMprescription
4. FollowingMU.S.MDrugMEnforcementMAdministrationMguidelinesMforMprescribing
M 5.MNurseMpractitionerMpracticeMmayMthriveMunderMhealth-careMreformMbecauseM of:
1. TheMdemonstratedMabilityMofMnurseMpractitionersMtoMcontrolMcostsMandMimproveMpati
entMoutcomes
2. TheMfactMthatMnurseMpractitionersMwillMbeMableMtoMpracticeMindependently
3. TheMfactMthatMnurseMpractitionersMwillMhaveMfullMreimbursementMunderMheal
th-McareMreform
4. TheMabilityMtoMshiftMaccountabilityMforMMedicaidMtoMtheMstateMlevel
, Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 5th
M M M M M M M
edition Woo Robinson Test Bank
M M M M M
ChapterM1.MTheMRoleMofMtheMNurseMPractitionerMasMPrescrib
erMAnswerMSection
MULTIPLEMCHOICE
1.MANS: 3 PTS: 1
2.MANS: 2 PTS: 1
3.MANS: 1 PTS: 1
4.MANS: 2 PTS: 1
5.MANS: 1 PTS: 1
, Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 5th
M M M M M M M
edition Woo Robinson Test Bank
M M M M M
ChapterM2.MReviewMofMtheMBasicMPrinciplesMofMPharmacolog
yMMultipleMChoice
IdentifyMtheMchoiceMthatMbestMcompletesMtheMstatementMorManswersMtheMquestion.
M 1.MAMpatient’sMnutritionalMintakeMandMlaboratoryMresultsMreflectMhypoalbuminemia.MThisMisMcritica
lMtoMprescribingMbecause:
1. DistributionMofMdrugsMtoMtargetMtissueMmayMbeMaffected.
2. TheMsolubilityMofMtheMdrugMwillMnotMmatchMtheMsiteMofMabsorption.
3. ThereMwillMbeMlessMfreeMdrugMavailableMtoMgenerateManMeffect.
4. DrugsMboundMtoMalbuminMareMreadilyMexcretedMbyMtheMkidneys.
M 2.MDrugsMthatMhaveMaMsignificantMfirst-passM effect:
1. MustMbeMgivenMbyMtheMenteralM(oral)MrouteMonly
2. BypassMtheMhepaticMcirculation
3. AreMrapidlyMmetabolizedMbyMtheMliverMandMmayMhaveMlittleMifManyMdesiredMaction
4. AreMconvertedMbyMtheMliverMtoMmoreMactiveMandMfat-solubleMforms
M 3.MTheMrouteMofM excretionMofMaMvolatileMdrugMwillMlikelyMbeM the:
1. Kidneys
2. Lungs
3. BileMandMfeces
4. Skin
M 4.MMedroxyprogesteroneM(DepoMProvera)MisMprescribedMintramuscularlyM(IM)MtoMcreateMaMstor
ageMreservoirMofMtheMdrug.MStorageMreservoirs:
1. AssureMthatMtheMdrugMwillMreachMitsMintendedMtargetMtissue
2. AreMtheMreasonMforMgivingMloadingMdoses
3. IncreaseMtheMlengthMofMtimeMaMdrugMisMavailableMandMactive
4. AreMmostMcommonMinMcollagenMtissues
M 5.MTheMNPMchoosesMtoMgiveMcephalexinMeveryM8MhoursM basedMonMknowledgeMofMtheM drug’s:
1. PropensityMtoMgoMtoMtheMtargetMreceptor
2. BiologicalMhalf-life
3. Pharmacodynamics
4. SafetyMandMsideMeffects
M 6.MAzithromycinMdosingMrequiresMthatMtheMfirstMday’sMdosageMbeMtwiceMthoseMofMtheMotherM4MdaysM
ofMtheMprescription.MThisMisMconsideredMaMloadingMdose.MAMloadingMdose:
1. RapidlyMachievesMdrugMlevelsMinMtheMtherapeuticMrange
2. RequiresMfour-MtoMfive-half-livesMtoMattain
3. IsMinfluencedMbyMrenalMfunction
4. IsMdirectlyMrelatedMtoMtheMdrugMcirculatingMtoMtheMtargetMtissues
M 7.MTheMpointMinMtimeMonMtheMdrugMconcentrationMcurveMthatMindicatesMtheMfirstMsignMofMaMtherapeuticM
effectMisMthe:
1. MinimumMadverseMeffectMlevel
2. PeakMofMaction
, Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 5th
M M M M M M M
edition Woo Robinson Test Bank
M M M M M
3. OnsetMofMaction
4. TherapeuticMrange
M 8.MPhenytoinMrequiresMthatMaMtroughMlevelMbeMdrawn.MPeakMandMtroughMlevelsMareM done:
1. WhenMtheMdrugMhasMaMwideMtherapeuticMrange
2. WhenMtheMdrugMwillMbeMadministeredMforMaMshortMtimeMonly
3. WhenMthereMisMaMhighMcorrelationMbetweenMtheMdoseMandMsaturationMofMreceptorMsites
4. ToMdetermineMifMaMdrugMisMinMtheMtherapeuticMrange
M 9.MAMlaboratoryMresultMindicatesMthatMtheMpeakMlevelMforMaMdrugMisMaboveMtheMminimumM toxicMconcentration.
ThisMmeansMthatMthe:
1. ConcentrationMwillMproduceMtherapeuticMeffects
2. ConcentrationMwillMproduceManMadverseMresponse
3. TimeMbetweenMdosesMmustMbeMshortened
4. DurationMofMactionMofMtheMdrugMisMtooMlong
M10.MDrugsMthatMareMreceptorMagonistsMmayMdemonstrateMwhatM property?
1. IrreversibleMbindingMtoMtheMdrugMreceptorMsite
2. UpregulationMwithMchronicMuse
3. DesensitizationMorMdownregulationMwithMcontinuousMuse
4. InverseMrelationshipMbetweenMdrugMconcentrationMandMdrugMaction
M11.MDrugsMthatMareMreceptorMantagonists,MsuchMasMbetaMblockers,MmayMcause:
1. DownregulationMofMtheMdrugMreceptor
2. AnMexaggeratedMresponseMifMabruptlyMdiscontinued
3. PartialMblockadeMofMtheMeffectsMofMagonistMdrugs
4. AnMexaggeratedMresponseMtoMcompetitiveMdrugMagonists
M12.MFactorsMthatMaffectMgastricMdrugMabsorptionMinclude:
1. LiverMenzymeMactivity
2. Protein-bindingMpropertiesMofMtheMdrugMmolecule
3. LipidMsolubilityMofMtheMdrug
4. AbilityMtoMchewMandMswallow
M13.MDrugsMadministeredMviaM IV:
1. NeedMtoMbeMlipidMsolubleMinMorderMtoMbeMeasilyMabsorbed
2. BeginMdistributionMintoMtheMbodyMimmediately
3. AreMeasilyMabsorbedMifMtheyMareMnonionized
4. MayMuseMpinocytosisMtoMbeMabsorbed
M14.MWhenMaMmedicationMisMaddedMtoMaMregimenMforMaMsynergisticMeffect,MtheMcombinedMeffectMofMtheMdrugsMis:
1. TheMsumMofMtheMeffectsMofMeachMdrugMindividually
2. GreaterMthanMtheMsumMofMtheMeffectsMofMeachMdrugMindividually
3. LessMthanMtheMeffectMofMeachMdrugMindividually
4. NotMpredictable,MasMitMvariesMwithMeachMindividual
M15.MWhichMofMtheMfollowingMstatementsMaboutMbioavailabilityMisMtrue?
1. BioavailabilityMissuesMareMespeciallyMimportantMforMdrugsMwithMnarrowMtherapeu
ticMrangesMorMsustained-releaseMmechanisms.
2. AllMbrandsMofMaMdrugMhaveMtheMsameMbioavailability.
Pharmacotherapeutics
PRACTICE NURSEforPRESCRIBERS,
Advanced Practice Nurse
M 5TH
M
M
Prescribers,
EDITION
M 5t W M M
M
M
M
M
M
h
OO edition
ROBINSON TESTBANK
Woo Robinson
M
Test Bank M M
M
M M
PharmacotherapeuticsMforMAdvancedMPracticeMNurseMPrescribers,M5thMeditionMWooMRobinsonMTestMBank
ChapterM1.MTheMRoleMofMtheMNurseMPractitionerMasMPrescrib
erMMultipleMChoice
IdentifyMtheMchoiceMthatMbestMcompletesMtheMstatementMorManswersMtheMquestion.
M 1.MNurseMpractitionerMprescriptiveMauthorityMisMregulatedM by:
1. TheMNationalMCouncilMofMStateMBoardsMofMNursing
2. TheMU.S.MDrugMEnforcementMAdministration
3. TheMStateMBoardMofMNursingMforMeachMstate
4. TheMStateMBoardMofMPharmacy
M 2.MTheMbenefitsMtoMtheMpatientMofMhavingManMAdvancedMPracticeMRegisteredMNurseM(APRN)Mpresc
riberMinclude:
1. NursesMknowMmoreMaboutMPharmacologyMthanMotherMprescribersMbecauseMtheyMtak
eMitMbothMinMtheirMbasicMnursingMprogramMandMinMtheirMAPRNMprogram.
2. NursesMcareMforMtheMpatientMfromMaMholisticMapproachMandMincludeMtheMpatien
tMinMdecisionMmakingMregardingMtheirMcare.
3. APRNsMareMlessMlikelyMtoMprescribeMnarcoticsMandMotherMcontrolledMsubstances.
4. APRNsMareMableMtoMprescribeMindependentlyMinMallMstates,MwhereasMaMphysicia
n’sMassistantMneedsMtoMhaveMaMphysicianMsupervisingMtheirMpractice.
M 3.MClinicalMjudgmentMinMprescribingM includes:
1. FactoringMinMtheMcostMtoMtheMpatientMofMtheMmedicationMprescribed
2. AlwaysMprescribingMtheMnewestMmedicationMavailableMforMtheMdiseaseMprocess
3. HandingMoutMdrugMsamplesMtoMpoorMpatients
4. PrescribingMallMgenericMmedicationsMtoMcutMcosts
M 4.MCriteriaMforMchoosingManMeffectiveMdrugMforMaMdisorderM include:
1. AskingMtheMpatientMwhatMdrugMtheyMthinkMwouldMworkMbestMforMthem
2. ConsultingMnationallyMrecognizedMguidelinesMforMdiseaseMmanagement
3. PrescribingMmedicationsMthatMareMavailableMasMsamplesMbeforeMwritingMaMprescription
4. FollowingMU.S.MDrugMEnforcementMAdministrationMguidelinesMforMprescribing
M 5.MNurseMpractitionerMpracticeMmayMthriveMunderMhealth-careMreformMbecauseM of:
1. TheMdemonstratedMabilityMofMnurseMpractitionersMtoMcontrolMcostsMandMimproveMpati
entMoutcomes
2. TheMfactMthatMnurseMpractitionersMwillMbeMableMtoMpracticeMindependently
3. TheMfactMthatMnurseMpractitionersMwillMhaveMfullMreimbursementMunderMheal
th-McareMreform
4. TheMabilityMtoMshiftMaccountabilityMforMMedicaidMtoMtheMstateMlevel
, Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 5th
M M M M M M M
edition Woo Robinson Test Bank
M M M M M
ChapterM1.MTheMRoleMofMtheMNurseMPractitionerMasMPrescrib
erMAnswerMSection
MULTIPLEMCHOICE
1.MANS: 3 PTS: 1
2.MANS: 2 PTS: 1
3.MANS: 1 PTS: 1
4.MANS: 2 PTS: 1
5.MANS: 1 PTS: 1
, Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 5th
M M M M M M M
edition Woo Robinson Test Bank
M M M M M
ChapterM2.MReviewMofMtheMBasicMPrinciplesMofMPharmacolog
yMMultipleMChoice
IdentifyMtheMchoiceMthatMbestMcompletesMtheMstatementMorManswersMtheMquestion.
M 1.MAMpatient’sMnutritionalMintakeMandMlaboratoryMresultsMreflectMhypoalbuminemia.MThisMisMcritica
lMtoMprescribingMbecause:
1. DistributionMofMdrugsMtoMtargetMtissueMmayMbeMaffected.
2. TheMsolubilityMofMtheMdrugMwillMnotMmatchMtheMsiteMofMabsorption.
3. ThereMwillMbeMlessMfreeMdrugMavailableMtoMgenerateManMeffect.
4. DrugsMboundMtoMalbuminMareMreadilyMexcretedMbyMtheMkidneys.
M 2.MDrugsMthatMhaveMaMsignificantMfirst-passM effect:
1. MustMbeMgivenMbyMtheMenteralM(oral)MrouteMonly
2. BypassMtheMhepaticMcirculation
3. AreMrapidlyMmetabolizedMbyMtheMliverMandMmayMhaveMlittleMifManyMdesiredMaction
4. AreMconvertedMbyMtheMliverMtoMmoreMactiveMandMfat-solubleMforms
M 3.MTheMrouteMofM excretionMofMaMvolatileMdrugMwillMlikelyMbeM the:
1. Kidneys
2. Lungs
3. BileMandMfeces
4. Skin
M 4.MMedroxyprogesteroneM(DepoMProvera)MisMprescribedMintramuscularlyM(IM)MtoMcreateMaMstor
ageMreservoirMofMtheMdrug.MStorageMreservoirs:
1. AssureMthatMtheMdrugMwillMreachMitsMintendedMtargetMtissue
2. AreMtheMreasonMforMgivingMloadingMdoses
3. IncreaseMtheMlengthMofMtimeMaMdrugMisMavailableMandMactive
4. AreMmostMcommonMinMcollagenMtissues
M 5.MTheMNPMchoosesMtoMgiveMcephalexinMeveryM8MhoursM basedMonMknowledgeMofMtheM drug’s:
1. PropensityMtoMgoMtoMtheMtargetMreceptor
2. BiologicalMhalf-life
3. Pharmacodynamics
4. SafetyMandMsideMeffects
M 6.MAzithromycinMdosingMrequiresMthatMtheMfirstMday’sMdosageMbeMtwiceMthoseMofMtheMotherM4MdaysM
ofMtheMprescription.MThisMisMconsideredMaMloadingMdose.MAMloadingMdose:
1. RapidlyMachievesMdrugMlevelsMinMtheMtherapeuticMrange
2. RequiresMfour-MtoMfive-half-livesMtoMattain
3. IsMinfluencedMbyMrenalMfunction
4. IsMdirectlyMrelatedMtoMtheMdrugMcirculatingMtoMtheMtargetMtissues
M 7.MTheMpointMinMtimeMonMtheMdrugMconcentrationMcurveMthatMindicatesMtheMfirstMsignMofMaMtherapeuticM
effectMisMthe:
1. MinimumMadverseMeffectMlevel
2. PeakMofMaction
, Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 5th
M M M M M M M
edition Woo Robinson Test Bank
M M M M M
3. OnsetMofMaction
4. TherapeuticMrange
M 8.MPhenytoinMrequiresMthatMaMtroughMlevelMbeMdrawn.MPeakMandMtroughMlevelsMareM done:
1. WhenMtheMdrugMhasMaMwideMtherapeuticMrange
2. WhenMtheMdrugMwillMbeMadministeredMforMaMshortMtimeMonly
3. WhenMthereMisMaMhighMcorrelationMbetweenMtheMdoseMandMsaturationMofMreceptorMsites
4. ToMdetermineMifMaMdrugMisMinMtheMtherapeuticMrange
M 9.MAMlaboratoryMresultMindicatesMthatMtheMpeakMlevelMforMaMdrugMisMaboveMtheMminimumM toxicMconcentration.
ThisMmeansMthatMthe:
1. ConcentrationMwillMproduceMtherapeuticMeffects
2. ConcentrationMwillMproduceManMadverseMresponse
3. TimeMbetweenMdosesMmustMbeMshortened
4. DurationMofMactionMofMtheMdrugMisMtooMlong
M10.MDrugsMthatMareMreceptorMagonistsMmayMdemonstrateMwhatM property?
1. IrreversibleMbindingMtoMtheMdrugMreceptorMsite
2. UpregulationMwithMchronicMuse
3. DesensitizationMorMdownregulationMwithMcontinuousMuse
4. InverseMrelationshipMbetweenMdrugMconcentrationMandMdrugMaction
M11.MDrugsMthatMareMreceptorMantagonists,MsuchMasMbetaMblockers,MmayMcause:
1. DownregulationMofMtheMdrugMreceptor
2. AnMexaggeratedMresponseMifMabruptlyMdiscontinued
3. PartialMblockadeMofMtheMeffectsMofMagonistMdrugs
4. AnMexaggeratedMresponseMtoMcompetitiveMdrugMagonists
M12.MFactorsMthatMaffectMgastricMdrugMabsorptionMinclude:
1. LiverMenzymeMactivity
2. Protein-bindingMpropertiesMofMtheMdrugMmolecule
3. LipidMsolubilityMofMtheMdrug
4. AbilityMtoMchewMandMswallow
M13.MDrugsMadministeredMviaM IV:
1. NeedMtoMbeMlipidMsolubleMinMorderMtoMbeMeasilyMabsorbed
2. BeginMdistributionMintoMtheMbodyMimmediately
3. AreMeasilyMabsorbedMifMtheyMareMnonionized
4. MayMuseMpinocytosisMtoMbeMabsorbed
M14.MWhenMaMmedicationMisMaddedMtoMaMregimenMforMaMsynergisticMeffect,MtheMcombinedMeffectMofMtheMdrugsMis:
1. TheMsumMofMtheMeffectsMofMeachMdrugMindividually
2. GreaterMthanMtheMsumMofMtheMeffectsMofMeachMdrugMindividually
3. LessMthanMtheMeffectMofMeachMdrugMindividually
4. NotMpredictable,MasMitMvariesMwithMeachMindividual
M15.MWhichMofMtheMfollowingMstatementsMaboutMbioavailabilityMisMtrue?
1. BioavailabilityMissuesMareMespeciallyMimportantMforMdrugsMwithMnarrowMtherapeu
ticMrangesMorMsustained-releaseMmechanisms.
2. AllMbrandsMofMaMdrugMhaveMtheMsameMbioavailability.
